Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Spondyloarthritis
•
Psoriatic arthritis
•
General Rheumatology
•
Cardiology
•
Cardio-Rheumatology
•
Pericarditis
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
Related Questions
How do you approach cardiovascular risk management in patients with rheumatic disease?
Would you switch to bimekizumab if a patient with psoriatic arthritis who is already on an IL-17 inhibitor has breakthrough skin or joint disease?
What is your approach to differentiating tender spots (as in fibromyalgia) and enthesitis (as in axSpA)?
Are there certain disease domains in a patient with psoriatic arthritis that will make bimekizumab a particularly good option?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
Do you generally attempt to taper and discontinue biologics in a patient with psoriatic arthritis who is in clinical remisson?
Where do you anticipate using bimekizumab in your sequence of treatment options for a patient with psoriatic arthritis?
How would you manage cardiac sarcoid with intolerance/contraindications to methotrexate, azathioprine, and mycophenolate/mycophenolic acid and that has proven refractory to adalimumab and infliximab as determined by PET?
Do you pursue coronary artery calcium scoring in patients with metabolic risk factors and autoimmune disease in order to guide decisions regarding GLP-1 medications?
Would you recommend avoiding use of bimekizumab in patients at higher risk of fungal infections such as patients with diabetes who are on SGLT-2 inhibitors which also increase the risk of fungal infections?
